Morgan Stanley
LABU icon

Morgan Stanley’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Morgan Stanley’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.64K Sell
40
-6,182
-99% -$1.01M ﹤0.01% 7069
2025
Q4 		$992K Sell
6,222
-36,667
-85% -$5.03M ﹤0.01% 5194
2025
Q3 		$4.01M Buy
42,889
+36,125
+534% +$2.55M ﹤0.01% 4323
2025
Q2 		$385K Sell
6,764
-3,268
-33% -$173K ﹤0.01% 5584
2025
Q1 		$612K Sell
10,032
-166
-2% -$14.1K ﹤0.01% 5243
2024
Q4 		$918K Buy
10,198
+1,073
+12% +$126K ﹤0.01% 5133
2024
Q3 		$1.17M Sell
9,125
-18,664
-67% -$2.44M ﹤0.01% 4954
2024
Q2 		$3.15M Sell
27,789
-22,086
-44% -$2.36M ﹤0.01% 4245
2024
Q1 		$6.62M Sell
49,875
-77,927
-61% -$10.2M ﹤0.01% 3684
2023
Q4 		$15.6M Buy
127,802
+111,138
+667% +$8.5M ﹤0.01% 3559
2023
Q3 		$1.27M Sell
16,664
-4,938
-23% -$507K ﹤0.01% 4653
2023
Q2 		$2.56M Buy
21,602
+13,275
+159% +$1.65M ﹤0.01% 4263
2023
Q1 		$818K Buy
8,327
+2,022
+32% +$274K ﹤0.01% 4969
2022
Q4 		$892K Buy
6,305
+1,483
+31% +$207K ﹤0.01% 4934
2022
Q3 		$676K Buy
4,822
+592
+14% +$109K ﹤0.01% 5108
2022
Q2 		$570K Buy
4,230
+1,366
+48% +$233K ﹤0.01% 5349
2022
Q1 		$897K Buy
2,864
+852
+42% +$321K ﹤0.01% 5075
2021
Q4 		$1.45M Buy
2,012
+494
+33% +$473K ﹤0.01% 4822
2021
Q3 		$1.68M Buy
1,518
+863
+132% +$1.06M ﹤0.01% 4711
2021
Q2 		$965K Buy
655
+411
+168% +$570K ﹤0.01% 5101
2021
Q1 		$385K Sell
244
-9
-4% -$21.1K ﹤0.01% 5303
2020
Q4 		$509K Sell
253
-582
-70% -$928K ﹤0.01% 5071
2020
Q3 		$894K Buy
835
+51
+7% +$58.5K ﹤0.01% 4286
2020
Q2 		$932K Buy
784
+469
+149% +$407K ﹤0.01% 4236
2020
Q1 		$142K Sell
315
-6,748
-96% -$6.14M ﹤0.01% 5032
2019
Q4 		$8.12M Buy
7,063
+4,316
+157% +$3.87M ﹤0.01% 2656
2019
Q3 		$1.7M Buy
2,747
+2,113
+333% +$1.76M ﹤0.01% 3927
2019
Q2 		$637K Sell
634
-5,963
-90% -$5.77M ﹤0.01% 4478
2019
Q1 		$7.9M Buy
6,597
+96
+1% +$99.9K ﹤0.01% 2268
2018
Q4 		$4.27M Buy
6,501
+4,004
+160% +$4.2M ﹤0.01% 3074
2018
Q3 		$4.65M Sell
2,497
-204
-8% -$401K ﹤0.01% 3260
2018
Q2 		$5.13M Buy
2,701
+488
+22% +$860K ﹤0.01% 3112
2018
Q1 		$3.52M Sell
2,213
-19
-0.9% -$35.4K ﹤0.01% 3430
2017
Q4 		$3.48M Buy
2,232
+390
+21% +$597K ﹤0.01% 3495
2017
Q3 		$3.15M Buy
1,842
+1,128
+158% +$1.57M ﹤0.01% 3437
2017
Q2 		$901K Buy
714
+58
+9% +$58.5K ﹤0.01% 4446
2017
Q1 		$626K Buy
656
+40
+6% +$35.6K ﹤0.01% 4692
2016
Q4 		$386K Buy
616
+534
+651% +$401K ﹤0.01% 5065
2016
Q3 		$80K Sell
82
-145
-64% -$120K ﹤0.01% 5399
2016
Q2 		$128K Buy
227
+120
+112% +$75.2K ﹤0.01% 5131
2016
Q1 		$59K Buy
+107
New +$67.7K ﹤0.01% 5545
2015
Q4 		– Sell
-6
Closed -$8K – 6730
2015
Q3 		$8K Buy
+6
New +$18.3K ﹤0.01% 6292

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Morgan Stanley's LABU Position: Q1 2026 in Review

Morgan Stanley reduced its Direxion Daily S&P Biotech Bull 3X ETF (LABU) stake by 99% in Q1 2026, selling an estimated $1.01M and leaving 40 shares worth $6.64K. The position accounts for ﹤0.01% of the portfolio, ranked #7069.

Morgan Stanley first reported a position in LABU in Q3 2015 and has held it in 42 quarters since. The position peaked at $15.6M in Q4 2023. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • Morgan Stanley held 40 shares of Direxion Daily S&P Biotech Bull 3X ETF worth $6.64K as of Q1 2026.
  • Morgan Stanley sold 6,182 Direxion Daily S&P Biotech Bull 3X ETF shares in Q1 2026, an estimated $1.01M.
  • Direxion Daily S&P Biotech Bull 3X ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7069 holding.
  • Morgan Stanley first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q3 2015 and has held it in 42 quarters since.
  • Morgan Stanley's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $15.6M in Q4 2023.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.